Symphony Asset Management’s Charles River Laboratories CRL Stock Holding History

Symphony Asset Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,466	Closed	-$224K	–	71
2019 Q4	$224K	Sell	1,466 -51	-3%	-$7.06K	0.05%	151
2019 Q3	$201K	Sell	1,517 -51	-3%	-$6.84K	0.04%	168
2019 Q2	$222K	Sell	1,568 -28	-2%	-$3.8K	0.05%	151
2019 Q1	$232K	Sell	1,596 -670	-30%	-$88K	0.06%	149
2018 Q4	$256K	Sell	2,266 -70	-3%	-$8.76K	0.08%	132
2018 Q3	$314K	Sell	2,336 -155	-6%	-$19.1K	0.08%	139
2018 Q2	$278K	Sell	2,491 -3,815	-60%	-$412K	0.06%	195
2018 Q1	$673K	Sell	6,306 -57	-0.9%	-$6.14K	0.09%	207
2017 Q4	$697K	Sell	6,363 -186	-3%	-$20.2K	0.07%	220
2017 Q3	$708K	Sell	6,549 -445	-6%	-$45.7K	0.08%	221
2017 Q2	$708K	Buy	+6,994	New	+$644K	0.08%	222

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Symphony Asset Management's CRL Position: Q1 2020 in Review

Symphony Asset Management sold out of Charles River Laboratories (CRL) in Q1 2020, closing a stake of 1,466 shares — an estimated $224K sold.

Symphony Asset Management first reported a position in CRL in Q2 2017 and held it in 11 quarters. The position peaked at $708K in Q3 2017. 414 funds tracked by Wall St. Rank hold CRL as of Q1 2020.

Symphony Asset Management reported no remaining Charles River Laboratories position as of Q1 2020 after selling out during the quarter.
Symphony Asset Management sold 1,466 Charles River Laboratories shares in Q1 2020, an estimated $224K.
Symphony Asset Management first reported a position in Charles River Laboratories in Q2 2017 and held it in 11 quarters.
Symphony Asset Management's Charles River Laboratories position peaked at $708K in Q3 2017.
414 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2020.

Based on Symphony Asset Management's 13F filing for Q1 2020, filed 12 May 2020.